Alivus Life Sciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Profit before tax (PBT) rose 12.81% YoY to Rs 215.79 crore in Q4 FY26.

EBITDA stood at Rs 237.3 crore, registering the growth of 13.8%, compared with Rs 208.5 crore posted in Q4 FY25. EBITDA margin improved to 34.4% in Q4 FY26 as against 32.1% in Q4 FY25.

Revenue from generic API segment rose 6.77% to Rs 634.3 crore while revenue from CDMO segment stood at Rs 45.3 crore, up 4.38% from 43.4 crore recorded in Q4 FY25.

On full year basis, the company?s standalone net profit climbed 16.24% to Rs 564.48 crore on 6.91% rise in revenue from operations to Rs 2551.83 crore in FY26 over FY25.

During FY26, the company generated a strong free cash flow of Rs 259 crore leading to cash and cash equivalents (including short term investments) of Rs 782.4 crore as of March 31, 2026.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, ?The past two years under Nirma's ownership have been deeply fulfilling ? a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth.

Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%

For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.?

Tushar Mistry, CFO, Alivus Life Sciences, said, ?For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30?32%, driven by a favourable product mix and disciplined control over operating expenses.?

Meanwhile, the company?s board recommended payment of final equity dividend of Rs 5 per equity share of face value Rs 2 each for FY26.

Alivus Life Sciences (formerly Glenmark Life Sciences) is engaged in the development and manufacturing of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.

Powered by Capital Market - Live News

Profit before tax (PBT) rose 12.81% YoY to Rs 215.79 crore in Q4 FY26.

EBITDA stood at Rs 237.3 crore, registering the growth of 13.8%, compared with Rs 208.5 crore posted in Q4 FY25. EBITDA margin improved to 34.4% in Q4 FY26 as against 32.1% in Q4 FY25.

Revenue from generic API segment rose 6.77% to Rs 634.3 crore while revenue from CDMO segment stood at Rs 45.3 crore, up 4.38% from 43.4 crore recorded in Q4 FY25.

On full year basis, the company?s standalone net profit climbed 16.24% to Rs 564.48 crore on 6.91% rise in revenue from operations to Rs 2551.83 crore in FY26 over FY25.

During FY26, the company generated a strong free cash flow of Rs 259 crore leading to cash and cash equivalents (including short term investments) of Rs 782.4 crore as of March 31, 2026.

Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, ?The past two years under Nirma's ownership have been deeply fulfilling ? a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth.

Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%

For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.?

Tushar Mistry, CFO, Alivus Life Sciences, said, ?For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30?32%, driven by a favourable product mix and disciplined control over operating expenses.?

Meanwhile, the company?s board recommended payment of final equity dividend of Rs 5 per equity share of face value Rs 2 each for FY26.

Alivus Life Sciences (formerly Glenmark Life Sciences) is engaged in the development and manufacturing of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.

The counter declined 1.68% to settle at Rs 1,044.85 on the BSE.

Powered by Capital Market - Live News

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.

Net profit of Alivus Life Sciences rose 14.65% to Rs 162.66 crore in the quarter ended March 2026 as against Rs 141.87 crore during the previous quarter ended March 2025. Sales rose 6.09% to Rs 689.12 crore in the quarter ended March 2026 as against Rs 649.55 crore during the previous quarter ended March 2025.

For the full year,net profit rose 16.24% to Rs 564.48 crore in the year ended March 2026 as against Rs 485.63 crore during the previous year ended March 2025. Sales rose 6.91% to Rs 2551.83 crore in the year ended March 2026 as against Rs 2386.88 crore during the previous year ended March 2025.

Powered by Capital Market - Live News